gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Oct 2014.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, Raf, CAN, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
The Wnt Signalling Cascade and the Adherens Junction Complex in Craniopharyngioma Tumorigenesis.
New
Grossman et al., Oxford, United Kingdom. In Endocr Pathol, 30 Nov 2014
No such mutational event has been associated with pCPs, where the BRAF gene appears to be more important.
Primary Cutaneous Small/Medium CD4+ T-Cell Lymphoma Occurring During Treatment With Vemurafenib for Advanced Melanoma.
New
Rodriguez-Peralto et al., Madrid, Spain. In Am J Dermatopathol, 29 Nov 2014
UNLABELLED: : The discovery of BRAF mutations in 40%-60% of melanomas led to the development of BRAF inhibitors, which exhibit objective response in over 50% of patients.
Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience.
New
Cabanillas et al., In J Clin Endocrinol Metab, 29 Nov 2014
UNLABELLED: Context: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation.
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E mutant metastatic melanoma.
New
Smyth et al., Annaba, Algeria. In Cancer Res, 28 Nov 2014
To address this question, we developed a metastatic BRAFV600E mutant melanoma cell line and demonstrated that the anti-metastatic properties of BRAF inhibitor PLX4720 (a research analogue of Vemurafenib) require host NK cells and perforin.
BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
New
Oláh et al., Szeged, Hungary. In J Eur Acad Dermatol Venereol, 28 Nov 2014
The BRAF mutation status of our patients does not seem to correlate with the extent and/or the outcome of the disease.
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy.
Review
New
van Amerongen et al., Amsterdam, Netherlands. In Cancer Res, 15 Nov 2014
UNLABELLED: Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors.
Review of the current targeted therapies for non-small-cell lung cancer.
Review
New
Wakelee et al., Stanford, United States. In World J Clin Oncol, 10 Nov 2014
Emerging therapies directed against other driver oncogenes in NSCLC including ROS1, HER2, and BRAF are covered as well.
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
New
Impact
Gonzalez et al., Nashville, United States. In J Clin Oncol, 06 Nov 2014
PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors.
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
New
Impact
Ribas et al., Bergamo, Italy. In N Engl J Med, 29 Oct 2014
UNLABELLED: Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone.
Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?
Review
New
Rots et al., Groningen, Netherlands. In Biochim Biophys Acta, 27 Oct 2014
Particularly, we propose to stratify patients based on common ovarian cancer mutations (KRAS, BRAF, ERBB2, BRCA1 and its link with estradiol, TP53) for future NRF2 targeting strategies.
Novel Approaches in Anaplastic Thyroid Cancer Therapy.
Review
New
Chen et al., Madison, United States. In Oncologist, 26 Oct 2014
This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways.
Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
New
Impact
Malek et al., San Francisco, United States. In Cancer Cell, 08 Oct 2014
Numerous oncogenic mutations occur within the BRAF kinase domain (BRAF(KD)).
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
New
Impact
Vagner et al., Villejuif, France. In Nature, 04 Oct 2014
In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway, on activation of the alternative, PI(3)K-AKT-mTOR, pathway (which is ERK independent) or on modulation of the caspase-dependent apoptotic cascade.
Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma.
Review
New
Kim, Taegu, South Korea. In Endocrinol Metab (seoul), 30 Sep 2014
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance.
Systemic treatment for BRAF-mutant melanoma: where do we go next?
New
Impact
Long et al., Sydney, Australia. In Lancet Oncol, Aug 2014
After decades of treatment failure for metastatic melanoma, the development of BRAF inhibitors was highly anticipated to dramatically improve outcomes for patients with oncogene-addicted BRAF-mutant metastatic melanoma.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., İzmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends